Tuesday, October 26, 2021

Glenmark launches unique fixed dose combination drug for diabetes

Glenmark launches unique fixed dose combination drug for diabetes The Mumbai based drug firm said it has introduced fixed dose combination (FDC) of its novel, patent protected Sodium Glucose Co-Transporter Inhibitor (SGLT2i) – Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) – Vildagliptin, with Metformin.

from Moneycontrol Business News https://ift.tt/3pDpXc4
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Bajaj Auto shares fall 2% as firm, subsidiary fall prey to ransomware attack

Bajaj Auto shares dipped 2% following a ransomware attack on its systems and subsidiary, Bajaj Auto Technology Ltd, on June 23, 2026. The co...